108 related articles for article (PubMed ID: 16970154)
1. [Distribution features of Gleason score and its relationship with clinical stages in 346 prostate cancer patients].
Wang S; Xie LP; Shen HF; Zheng XY; Qin J; Bai Y; Zhang CG; Chen ZD; Cai SL; Zhang ZG; Ren GP; Wang LJ; Yu XR
Zhonghua Nan Ke Xue; 2006 Aug; 12(8):689-92. PubMed ID: 16970154
[TBL] [Abstract][Full Text] [Related]
2. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
[TBL] [Abstract][Full Text] [Related]
3. [Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy].
Guan YB; Zhang YF; Wen H; Zhou SQ; Dai YT
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):801-5. PubMed ID: 19947562
[TBL] [Abstract][Full Text] [Related]
4. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
[TBL] [Abstract][Full Text] [Related]
5. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
6. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
[TBL] [Abstract][Full Text] [Related]
7. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993.
Gilliland FD; Gleason DF; Hunt WC; Stone N; Harlan LC; Key CR
J Urol; 2001 Mar; 165(3):846-50. PubMed ID: 11176484
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer volume at biopsy predicts clinically significant upgrading.
Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
[TBL] [Abstract][Full Text] [Related]
9. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
10. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
[TBL] [Abstract][Full Text] [Related]
11. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
12. [Mitochondrial function score combined with Gleason score for predicting the progression of prostate cancer].
Yu JJ; Yan T; Jiang YC
Zhonghua Nan Ke Xue; 2010 Mar; 16(3):220-2. PubMed ID: 20369548
[TBL] [Abstract][Full Text] [Related]
13. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
14. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
Stav K; Judith S; Merald H; Leibovici D; Lindner A; Zisman A
Urol Oncol; 2007; 25(5):383-6. PubMed ID: 17826654
[TBL] [Abstract][Full Text] [Related]
15. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
18. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
19. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
Coard KC; Skeete DH
BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]